Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESGO 2021 | Immune checkpoint inhibitors for endometrial and cervical cancer

Mansoor Mirza • 24 Oct 2021
ESGO 2021
Gynecological Cancer Antibodies Bevacizumab Cemiplimab Cisplatin Dostarlimab Lenvatinib Pembrolizumab

Mansoor Raza Mirza, MD, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, discusses recent improvements in immune-oncology, specifically immune checkpoint inhibitors, for patients with endometrial or cervical cancer. There have been big developments in this field in recent years, with several therapies being approved in the EU and USA. Several Phase III trials are likely to produce interesting data in the near future. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.

More from Mansoor Mirza

2:11
Long-term benefit from 1L maintenance PARP inhibitors in ovarian cancer
Mansoor Mirza • 29 Sep 2022
4:15
Optimal management of recurrent low grade endometrial cancer
Mansoor Mirza • 29 Sep 2022
2:20
ENGOT-EN1: carboplatin plus paclitaxel plus nintedanib for endometrial cancer
Mansoor Mirza • 24 Oct 2021
2:00
Highlights of ESGO 2021 for young researchers
Mansoor Mirza • 24 Oct 2021

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals